Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort
File(s)
Accepted version
Author(s)
Type
Journal Article
Abstract
Acrylamide, classified in 1994 by IARC as “probably carcinogenic to humans,” was discovered in 2002 in some heat-treated, carbohydrate-rich foods. Four prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The purpose of this nested case-control study, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, was to evaluate, for the first time, the association between hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) and the risk of developing EC in non-smoking postmenopausal women. Hemoglobin adducts were measured in red blood cells by HPLC/MS/MS. Four exposure variables were evaluated: HbAA, HbGA, their sum (HbAA+HbGA), and their ratio (HbGA/HbAA). The association between hemoglobin adducts and EC was evaluated using unconditional multivariable logistic regression models, and included 383 EC cases (171 were type-I EC), and 385 controls. Exposure variables were analyzed in quintiles based on control distributions. None of the biomarker variables had an effect on overall EC (HRHbAA;Q5vsQ1: 0.84, 95%CI: 0.49–1.48; HRHbGA;Q5vsQ1: 0.94, 95%CI: 0.54–1.63) or type-I EC risk. Additionally, none of the subgroups investigated (BMI < 25 vs. ≥25 kg m−2, alcohol drinkers vs. never drinkers, oral contraceptive users vs. non-users) demonstrated effect measure modification. Hemoglobin adducts of acrylamide or glycidamide were not associated with EC or type-I EC risk in 768 nonsmoking postmenopausal women from the EPIC cohort.
Date Issued
2015-09-16
Date Acceptance
2015-07-21
Citation
International Journal of Cancer, 2015, 138 (5), pp.1129-1138
ISSN
1097-0215
Publisher
Wiley
Start Page
1129
End Page
1138
Journal / Book Title
International Journal of Cancer
Volume
138
Issue
5
Copyright Statement
© 2015 UICC. This is the peer reviewed version of the following article: Obón-Santacana, M., Freisling, H., Peeters, P. H., Lujan-Barroso, L., Ferrari, P., Boutron-Ruault, M.-C., Mesrine, S., Baglietto, L., Turzanski-Fortner, R., Katzke, V. A., Boeing, H., Quirós, J. R., Molina-Portillo, E., Larrañaga, N., Chirlaque, M.-D., Barricarte, A., Khaw, K.-T., Wareham, N., Travis, R. C., Merritt, M. A., Gunter, M. J., Trichopoulou, A., Lagiou, P., Naska, A., Palli, D., Sieri, S., Tumino, R., Fiano, V., Galassom, R., Bueno-de-Mesquita, H. B., Onland-Moret, N. C., Idahl, A., Lundin, E., Weiderpass, E., Vesper, H., Riboli, E. and Duell, E. J. (2016), Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort. Int. J. Cancer, 138: 1129–1138., which has been published in final form at https://dx.doi.org/10.1002/ijc.29853
Sponsor
University Medical Center Utrecht
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000369164700010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
N/A
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
hemoglobin adduct
acrylamide
glycidamide
endometrial cancer
EPIC
DIETARY ACRYLAMIDE
EXPOSURE
ASSOCIATIONS
BIOMARKERS
OVARIAN
BREAST
MODEL
FOOD
Acrylamide
Biomarkers
Case-Control Studies
Endometrial Neoplasms
Epoxy Compounds
Female
Hemoglobins
Humans
Middle Aged
Postmenopause
Prospective Studies
Risk
Oncology & Carcinogenesis
1112 Oncology And Carcinogenesis
Publication Status
Published